Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population

Annals of Human Biology

Volumn 42, Issue 3, 2015, Pages 283-289

  Melo, Mafalda S ^a,b   Balanco, Leticia ^a,b   Branco, Claudia C ^a,c,d   Mota Vieira, Luisa ^a,c,d  

^a Molecular Genetics and Pathology Unit Hospital of Divino Espírito Santo of Ponta Delgada EPE   (Portugal)

^b UNIVERSITY OF THE AZORES   (Portugal)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

Azores; cardiovascular diseases; pharmacogenetics; polymorphisms; statins

Indexed keywords

ALLELE; ANNUAL VARIATION; CARDIOVASCULAR DISEASE; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; MUTATION; POLYMORPHISM; PUBLIC HEALTH; RISK FACTOR;

AZORES; PORTUGAL;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AZORES; FEMALE; GENE FREQUENCY; HUMAN; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

AZORES; FEMALE; GENE FREQUENCY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84940550919     PISSN: 03014460     EISSN: 14645033     Source Type: Journal    
DOI: 10.3109/03014460.2014.955056     Document Type: Article

References (30)

1. Anoop S, Misra A, Meena K, Luthra K. 2010. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. Indian J Med Res 132:363-378.
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
3. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, et al. 2005. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111:278-287.
4. Branco CC, Palla R, Lino S, Pacheco PR, Cabral R, De Fez L, Peixoto BR, Mota-Vieira L. 2006. Assessment of Azorean ancestry by Alu insertion polymorphisms. Am J Hum Biol 18:223-226.
5. Branco CC, Saõ Bento M, Gomes CT, Cabral R, Pacheco PR, Mota-Vieira L. 2008. Azores Islands: genetic origin, gene flow and diversity patterns. Ann Hum Biol 35:65-74.
6. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, Salit J, et al. 2008. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon 13. Arterioscler Thromb Vasc Biol 28:2078-2084.
7. Canestaro WJ, Austin MA, Thummel KE. 2014. Genetic factors affecting statin concentrations and subsequent myopathy: A HuGENet systematic review. Genet Med. [Epub ahead of print]. doi: 10.1038/gim.2014.41.
8. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton Jr VP, Ridke PM. 2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827.
9. Cholesterol Treatment Trialists' (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: A metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681.
10. Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, Donnan PT, Palmer CN. 2008. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: A GoDARTS study. Pharmacogenet Genomics 18:1021-1026.
11. Drögemöller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, et al. 2013. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 4:17.
12. Excoffier L, Laval G, Schneider S. 2005. Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evol Bioinformat Online 1:47-50.
13. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343:425-430.
14. Joseph PG, Pare G, Ross S, Roberts R, Anand SS. 2014. Pharmacogenetics in cardiovascular disease: The challenge of moving from promise to realization: Concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. Clin Cardiol 37:48-50.
15. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. 1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 338:86-93.
16. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, et al, SEARCH Collaborative Group. 2008. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359: 789-799.
17. Medina MW, Sangkuhl K, Klein TE, Altman RB. 2011. PharmGKB: very important pharmacogene-HMGCR. Pharmacogenet Genomics 21:98-101.
18. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. 2009. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29:1310-1315.
19. Mota-Vieira L, Pacheco PR, Almeida ML, Cabral R, Carvalho J, Branco CC, de Fez L, Peixoto BR, Araújo AL, Mendonça P. 2005. Human DNA bank in Saõ Miguel Island (Azores), a resource for genetic diversity studies. In: Amorim A, Côrte-Real F, Morling N, editors. Progress in forensic genetics proceedings, vol. 1288. Amsterdam: Elsevier BV. p 388-390.
20. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ. 1995. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Atherosclerosis 113:157-166.
21. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879.
22. Pavlovic S, Zukic B, Nikcevic G. 2012. Pharmacogenomics of thiopurine S-methyltransferase: Clinical applicability of genetic variants. In: Sanoudou D, editor. Clinical applications of pharmacogenetics. Rijeka, Croatia: InTech. p 75-94.
23. Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. 2010. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 29:629-37.
24. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, et al. 2008. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: An adverse pharmacogenetic interaction. Eur Heart J 29:2792-2799.
25. Rodrigues MO, Fonseca A, Matias Dias C, Albergaria I, Martins G, Alpendre ML, Martins Mdo C. 2005. APOE genotypes and dyslipidemias in a sample of the Portuguese population. Clin Chem Lab Med 43:907-912.
26. Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH. 2012. Pharmacogenomic diversity among Brazilians: Influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 3:191.
27. Superko HR, Momary KM, Li Y. 2012. Statins personalized. Med Clin N Am 96:123-139.
28. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, et al. 2005. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5: 352-358.
29. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. 2009. The SLCO1B1∗5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609-1616.
30. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC). 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatininduced myopathy. Clin Pharmacol Ther 92:112-117.